<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 12B-25
Commission File Number 000-09428
NOTIFICATION OF LATE FILING
(Check One): [ ] Form 10-K [ ] Form 11-K [ ] Form 20-F [X] Form 10-Q
[ ] Form N-SAR
For Period Ended: June 30, 1999
---------------------------------------------------------------
[ ] Transition Report on Form 10-K
[ ] Transition Report on Form 20-F
[ ] Transition Report on Form 11-K
[ ] Transition Report on Form 10-Q
[ ] Transition Report on Form N-SAR
For the Transition Period Ended:
----------------------------------------------
Read attached instruction sheet before preparing form. Please print or type.
Nothing in this form shall be construed to imply that the Commission has
verified any information contained herein.
If the notification relates to a portion of the filing checked above,
identify the Item(s) to which the notification relates:
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
<PAGE>
PART I--REGISTRANT INFORMATION
Full name of registrant SpectruMedix Corporation
---------------------------------------------------------
Former name if applicable
- --------------------------------------------------------------------------------
Address of principal executive office (Street and number)
2124 Old Gatesburg Road
- --------------------------------------------------------------------------------
City, State and Zip Code State College, Pennsylvania 16803
--------------------------------------------------------
PART II--RULES 12B-25(B) AND (C)
If the subject report could not be filed without unreasonable effort or
expense and the registrant seeks relief pursuant to Rule 12b-25(b), the
following should be completed. (Check box if appropriate)
[X] (a) The reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or expense;
[ ] (b) The subject annual report, semi-annual report, transition report
on Form 10-K, 20-F, 11-K or Form N-SAR or portion thereof will
be filed on or before the 15th calendar day following the prescribed
due date; or the subject quarterly report or transition report on
Form 10-Q, or portion thereof will be filed on or before the fifth
calendar day following the prescribed due date; and
[ ] (c) The accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
PART III--NARRATIVE
State below in reasonable detail the reasons why the Form 10-K, 20-F,
10-Q, N-SAR or the transition report or portion thereof could not be filed
within the prescribed time period. (Attach extra sheets if needed.)
SpectruMedix Corporation, a Delaware Corporation (the "Registrant"),
is finalizing its Annual Report on Form 10-K for the year ended March 31, 1999,
which the Registrant intends to file as soon as practicable. The Registrant was
not able to file such annual report because management's attention was focused
on restructuring certain material agreements. The Form 10-Q for the quarter
ended June 30, 1999 will be filed promptly after the Registrant's files its
Annual Report on Form 10-K for the year ended March 31, 1999.
PART IV--OTHER INFORMATION
(1) Name and telephone number of person to contact in regard to this
notification
Karl Fazler (814) 867-7600
- ------------------------------------ ----------- -------------------------
(Name) (Area Code) (Telephone Number)
(2) Have all other periodic reports required under Section 13 or 15(d) of
the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act
of 1940 during the preceding 12 months or for such shorter period that the
registrant was required to file such report(s) been filed? If the answer is no,
identify report(s).
[ ] Yes [X] No
2.
<PAGE>
The Registrant failed to filed its Annual Report on Form 10-K for the year
ended March 31, 1999, which the Registrant intends to file as soon as
practicable.
(3) Is it anticipated that any significant change in results of operations
from the corresponding period for the last fiscal year will be reflected by the
earnings statements to be included in the subject report or portion thereof?
[ ] Yes [X] No
If so: attach an explanation of the anticipated change, both narratively
and quantitatively, and, if appropriate, state the reasons why a reasonable
estimate of the results cannot be made.
SpectruMedix Corporation
- ------------------------------------------------------------------------------
(Name of Registrant as specified in charter)
Has caused this notification to be signed on its behalf by the undersigned
thereunto duly authorized.
Date August 16, 1999 By /s/ Joseph K. Alderstein
---------------------------------- --------------------------------------
Name: Joseph K. Alderstein
Title: President and Chief Executive
Officer
3.
